Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

Inclusion Criteria: * Severe haemophilia A (FVIII level less than or equal to 1%) * Treatment history of more than 150 exposure days with recombinant or plasma-derived FVIII replacement products * HIV or HCV negative, or if positive the patient is on a stable antiviral regimen at the time of the enrolment in the trial Exclusion Criteria: * Presence of any bleeding disorder in addition to haemophilia A * Inhibitor titre greater than or equal to 0.6 Bethesda Units (BU) at screening and past history of inhibitor * Abnormal renal function tests * Known hypersensitivity to Advate®